MiRNAs with apoptosis regulating potential are differentially expressed in chronic exercise-induced physiologically hypertrophied hearts

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Ramasamy, Subbiah ^a   Velmurugan, Ganesan ^a   Rajan, K Shanmugha ^a   Ramprasath, Tharmarajan ^b   Kalpana, Krishnan ^c  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TAMIL NADU AGRICULTURAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 10; MICRORNA 100; MICRORNA 133; MICRORNA 181A; MICRORNA 191A; MICRORNA 19B; MICRORNA 208A; MICRORNA 22; MICRORNA 30E; MICRORNA 99B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EXERCISE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; RAT; RNA ANALYSIS; RNA SEQUENCE; SIGNAL TRANSDUCTION; SWIMMING; ANIMAL; CARDIOMEGALY; DOWN REGULATION; GENE ONTOLOGY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; UPREGULATION; WISTAR RAT;

RATTUS;

ANIMALS; APOPTOSIS; CARDIOMEGALY; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; MICRORNAS; PHYSICAL CONDITIONING, ANIMAL; RATS, WISTAR; UP-REGULATION;

EID: 84925869307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121401     Document Type: Article

References (31)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 2003; 65: 45-79. PMID: 12524460
2. Dorn GW. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007; 49: 962-970. PMID: 17389260
3. Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Cell. Mol. Biol. 2013; 14: 38-48.
4. Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A metanalysis of cardiac structure and function. Circulation. 2000; 101: 336-344. PMID: 10645932
5. Archer E, Blair SN. Physical activity and the prevention of cardiovascular disease: from evolution to epidemiology. Prog. Cardiovasc. Dis. 2011; 53: 387-396. doi: 10.1016/j.pcad.2011.02.006 PMID: 21545924
6. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin. Expert. Pharmacol. 2007; 34: 255-262.
7. Bernado BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Therapeutics. 2010; 128:191-227. doi: 10.1016/j.pharmthera.2010.04.005 PMID: 20438756
8. Da Costa Martins PA, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc. Res. 2012; 93: 563-572. doi: 10.1093/cvr/cvs013 PMID: 22266752
9. Soci UPR, Fernandes T, Hashimato NY, Mota GF, Amadeu MA, Rosa KT, et al. MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. Physiol. Genomics. 2011; 43: 665-673. doi: 10.1152/physiolgenomics.00145.2010 PMID: 21447748
10. Fernandes T, Soci UP, Oliveira EM. Eccentric and concentric cardiac hypertrophy induced by exercise training: microRNAs and molecular determinants. Braz. J. Med. Biol. Res. 2011; 44: 836-847. PMID: 21881810
11. DA Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI, DE Oliveira EM. Swimming training in rats increases cardiac microRNA-126 expression and angiogenesis. Med. Sci. Sports Exerc. 2012; 44: 1453-1462. doi: 10.1249/MSS.0b013e31824e8a36 PMID: 22330028
12. Martinelli NC, Cohen CR, Santos KG, Castro MA, Biolo A, Frick L, et al. An analysis of the global expression of MicroRNAs in an Experimental Model of Physiological Left Ventricular Hypertrophy, PLoS One. 2014; 9: e93271. doi: 10.1371/journal.pone.0093271 PMID: 24751578
13. Balakumar P, Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin. Pharmacol. Toxicol. 2006; 99: 418-424. PMID: 17169122
14. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. Cell profiler: image analysis software for identifying and quantifying cell phenotypes, Genome Biol. 2006; 7: R100. PMID: 17076895
15. An J, Lai J, Lehman ML, Nelson. CC. miRDeep∗: an integrated application tool for miRNA identification from RNA sequencing data. Nucleic Acids Res. 2013; 41: 727-737. doi: 10.1093/nar/gks1187 PMID: 23221645
16. Freidlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately identified known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acid Res. 2012; 40: 37-52. doi: 10.1093/nar/gkr688 PMID: 21911355
17. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010; 11: R106. doi: 10.1186/gb-2010-11-10-r106 PMID: 20979621
18. Dweep H, Sticht C, Pandey P, Gretz, N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed. Inform. 2011; 44: 839-847. doi: 10.1016/j.jbi.2011.05.002 PMID: 21605702
19. Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol. 2011; 11: 70. doi: 10.1186/1472-6750-11-70 PMID: 21702990
20. Eden E, Navon R, Steinfeld I, Lipson, D, Yakhini Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009; 10: 48. doi: 10.1186/1471-2105-10- 48 PMID: 19192299
21. Fernandes T, Hashimoto NY, Magalhaes FC, Fernandes FB, Casarini DE, Carmona AK, et al. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). Hypertension. 2011; 58: 182-189. doi: 10.1161/HYPERTENSIONAHA.110.168252 PMID: 21709209
22. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: Functional Correlates. J. Mol. Cell. Cardiol. 2008: 45: 185-192. doi: 10.1016/j.yjmcc.2008.04.014 PMID: 18582896
23. Coppola A, Romito A, Borel C, Gehrig C, Gagnebin M, Falconnet E. et al. Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications. Stem Cell Res. 2014; 12: 323-337. doi: 10.1016/j.scr.2013.11.008 PMID: 24365598
24. Nagpal N, Kulshreshtha R. miR-191: an emerging player in disease biology. Front. Genetics. 2014; 23: 99.
25. Huang ZP, Chen J, Seok HY, Zhang Z, Katoaka M, Hu X, et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circulation Res. 2013; 112: 1234-1243. doi: 10.1161/CIRCRESAHA.112.300682 PMID: 23524588
26. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA181-b regulates NF-kB mediated vascular inflammation. J. Clin. Invest. 2012; 122: 1973-1990. doi: 10.1172/JCI61495 PMID: 22622040
27. Song DW, Ryu JY, Kim JO, Kwon EJ, Kim do H. The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1.Biochem. J. 2014; 457: 151-162. doi: 10.1042/BJ20130833 PMID: 24117217
28. Pan W, Zhong Y, Cheng C, Liu B, Wang L, Li A, et al. miR-30-Regulated Autophagy Mediates Angiotensin II-Induced Myocardial Hypertrophy. PLoS One. 2013; 8: e53950. doi: 10.1371/journal.pone.0053950 PMID: 23326547
29. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007; 13: 613-618. PMID: 17468766
30. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011; 124: 1537-1547. doi: 10.1161/CIRCULATIONAHA.111.030932 PMID: 21900086
31. Kemi OJ, Ceci M, Wisloff U, Grimaldi S, Gallo P, Smith GL, et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J. Cell. Physiol. 2008; 214: 316-321. PMID: 17941081